Background-This study sought to systematically investigate the derivation of late outgrowth endothelial progenitor cells (late EPC) and mesenchymal stem cells (MSC) from umbilical cord blood (UCB) and to examine their therapeutic effects on myocardial infarction (MI).
Introduction
During the past decade, adult bone marrow (BM) was the major source of stem or progenitor cells such as hematopoietic stem cells (HSC), endothelial progenitor cells (EPC), and mesenchymal stem cells (MSC) for cell-based therapy. However, the aspiration of BM is an invasive procedure associated with risks such as infection, bleeding, or pain. Compared to BM, UCB has various benefits for clinical application due to the lack of viral contamination and easy access without invasive procedures or long-term storage [1] . Therefore, UCB has emerged as an attractive and alternative source for stem or progenitor cells for clinical application [2] [3] [4] .
To date, at least two distinctive types of cultured EPC have been reported: early and late outgrowth EPC. Early EPC are typically derived from culture of mononuclear cells (MNC) for less than a week and are characterized by a low proliferation rate [5] [6] [7] [8] . Late outgrowth EPC, also called outgrowth endothelial cells, late EPC, or endothelial colony forming cells, emerge as colonies after culture of MNC for 2 weeks or more and are characterized by cobblestone morphology and high proliferative potential [9] [10] [11] . These two types of EPC express different sets of cell surface markers. Early EPC express the pan-leukocyte marker CD45 and monocytic/macrophage markers CD11b/CD14. Late EPC express most of the endothelial cell markers but not hematopoietic cell markers. MSC are another representative adult stem cell which are frequently derived from BM and possess multipotency and paracrine effects [12, 13] . Over the past decade, BM-derived early EPC or MSC were shown to improve cardiovascular ischemia or infarct repair [14] [15] [16] [17] [18] [19] . However, most studies with EPC or MSC derived from UCB remain at the level of in vitro cell characterization [20] [21] [22] [23] [24] [25] [26] .
While several studies reported therapeutic effects of UCB-derived early EPC on myocardial infarction (MI), no studies have investigated the therapeutic potential of UCB-derived late EPC or MSC. Only a few studies are available which explored in vitro cardiomyogenic differentiation potential of UCB-derived MSC [27] . Accordingly, the present study sought to characterize UCB-derived late EPCs and -MSCs and determine their therapeutic effects in myocardial infarction and the underlying mechanisms.
Materials and Methods

Derivation and characterization of EPC and MSC
UCB was collected after receiving informed consent from the birthing mother using the guidelines approved by institutional review boards of Yonsei University. MNC were collected according to the previously published method [28] . Briefly, MNC were obtained by Ficoll-Hypaque (Amersham Biosciences, Sunnyvale, CA) density gradient centrifugation. The MNC were harvested from the interface, washed two to three times, plated on cell culture dishes coated with 0.01% human fibronectin (Sigma, St. Louis, MO) at a density of 0.5 to 1×10 6 cells/cm2, and cultured in endothelial growth medium-2 (EGM-2, Cambrex, Walkersville, MD). Non-adherent cells were removed during medium changes after 72 hours and the adherent cells were fed twice a week with fresh culture medium. Cell expansion culture was performed with EGM-2 for another three months.
Flow cytometry
Flow cytometry analyses of EPC and MSC were performed at passage 5 of culture as we previously described [29] . For flow cytometry analyses, we used FITC-or PE-conjugated Abs against CD29, CD31, CD34, CD44, CD45, CD73, CD90, CD105, CD144, CD146, vWF, HLA-DR (all from BD), KDR and Tie-2 (from R&D systems). The fluorescence intensities of the cells were evaluated by an FC 500 flow cytometer (BD) and the data were analyzed with FlowJo 7.
Tube formation assay
To investigate the tube formation potential, EPC and MSC were seeded onto Matrigelcoated dishes (BD) and cultured in complete EBM-2 medium at a concentration of 1 × 10 4 cells/well. After 24 hours of incubation, endothelial network formation was examined and representative fields were photographed under fluorescence microscopy.
Induction of myocardial infarction and cell transplantation
Male Sprague-Dawley rats (LabAnimal. Korea) and nude rats (Charles River Laboratories, Wilmington, MA) aged 8 weeks were used. All animal protocols were approved by the Institutional Animal Care and Use Committees at the Yonsei University and Emory University. For physiologic and functional studies we used Sprague-Dawley rats and for mechanistic studies we switched to nude rats to better elucidate mechanisms. Rats were anesthetized with Zoletil 50 (100mg/kg, Virbac), then intubated and ventilated using a small animal ventilation apparatus (Harvard apparatus, MA). MI was induced by ligation of the left anterior descending coronary artery as described previously [28] . One hour after MI, the rats received 5 × 10 6 EPC or MSC suspended in 50 µl of PBS intramyocardially. The same volume of PBS without cells was injected as a control. The cells or PBS were injected with a 31-gage needle attached to an insulin syringe.
Echocardiography
Echocardiography was performed 4 weeks after cell transplantation. The rats were anesthetized with inhalation of isoflurane. The echocardiographic images were obtained using Vivid 7 echocardiographic machine with 12 MHz phased array transducer (GE Medical Systems, Milwaukee, WI) [30] . Left ventricular (LV) M-mode and two dimensional imaging at the papillary muscle level were obtained by parasternal short axis view. The endsystolic inter-ventricular septum (IVSs), end-diastolic inter ventricular septum (IVSd), LV end-systolic dimension (LVESD), LV end-systolic posterior wall (LVPWs), and LV enddiastolic posterior wall (LVPWd) were measured on M-mode echocardiograms. These parameters allowed calculation of the LV fractional shortening (FS %) using the following equation: FS % = [(LVEDD−LVESD)/LVEDD] × 100%. The LV ejection fraction (EF %) was measured by a modified Quinone's method. All measurements were averaged for three consecutive cardiac cycles and all the parameters were analyzed by an observer blinded to the experiment.
Histological analysis
Rats were euthanized 2 or 4 weeks after cell transplantation. Hearts were harvested and fixed in 4% paraformaldehyde and incubated overnight in 15% sucrose solution. The tissues were embedded in OCT compound (Sakura Finetek), snap-frozen in liquid nitrogen, and sectioned at 10 -20 µm thickness as described previously by our laboratory [28] . For capillary density measurement, four frozen sections of ischemic tissues were stained with primary biotinylated isolectin B4 (ILB4) (1:250, Vector Laboratories, Inc., Burlingame, CA) and secondary streptavidin Alexafluor 488 (1:400, Invitrogen). Five fields from four tissue sections were randomly selected, and the number of capillaries was counted in each field. Photographs were taken using fluorescent inverted microscopy or confocal microscopy. To evaluate apoptosis, TdT-mediated dUTP nick-end labeling (TUNEL) reaction was performed using a fluorescein in situ cell death detection kit (Roche-Molecular). To investigate proliferative cells, immunostaining with anti-Ki-67 antibody (Novocastra Laboratories) was performed. Details of the above procedures were described in our prior publications [28, 31] .
Real-time RT-PCR (qRT-PCR)
qRT-PCR assay was performed as described previously [32] . Peri-infarct myocardial tissues were harvested and pulverized to extract RNA or protein. Total RNA was extracted using RNA-Stat (Iso-Tex Diagnostics) according to the manufacturer's instructions. cDNA was synthesized from the extracted RNA (500 ng) with Taqman Reverse Transcription Reagents (Applied Biosystems) and subjected to real-time polymerase chain reaction using human and rat-specific primers (Supplemental Table 1 ). qPCR was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems) using gene expression master mix and the TaqMan method (Applied Biosystems). Relative mRNA expression of target gene normalized to GAPDH was calculated as previously described [29] . Relative RNA expression was determined using the formula Rel Exp = 2 −ΔCT (fold difference), where ΔCt = (Ct of target genes) − (Ct of endogenous control gene, GAPDH) in experimental samples [29, 32] .
Statistical analysis
All data were presented as mean ± SD. Statistical analyses were performed with Student's ttest for comparisons between two groups, and ANOVA followed by Bonferroni's correction for more than two groups using SPSS version 11.0. P < 0.05 is considered statistical significance.
Results
Culture derivations of late EPCs and MSCs
After culturing UCB-derived MNC for 14-21 days under conventional EPC culture conditions, two types of dominant cell populations emerged in different dishes: cobblestonelike cells (identified as EPC) and spindle-shaped cells (identified as MSC) ( Figure 1A ). Due to unknown reasons, one type of cell usually dominates in one dish within several weeks. Cells of each type were further cultured and the distinction became clearer. Spindle-shaped cells or MSC were continuously cultured without significant signs of senescence or morphologic changes for more than 21 passages (over 3 months) and were expanded more than 1000-fold. EPC continued to proliferate for 4 weeks, albeit showing less proliferative potential. The mean doubling time of EPC and MSC were approximately 34 and 26 hours, respectively ( Figure 1B) . Twenty six units out of 48 units of cord blood (66%) generated EPC and 13 units out of 37 units (35%) generated MSC during cultivation.
Characterization of late EPC and MSC
Flow cytometry was used to characterize the two cell types. Cobblestone cells expressed CD31 (PECAM-1), CD34, CD105 (Endoglin), CD144 (VE-Cadherin), CD146 (MCAM), KDR (VEGFR-2), TIE-2, HLA-ABC, and HLA-DR, and were negative for CD45 (leukocyte common antigen), suggesting a late EPC phenotype ( Figure 1C ). The spindleshaped cells expressed CD29 (Integrin-β1), CD44 (hyaluronate receptor), CD73 (NT5E), CD90 (Thy-1), and HLA-ABC, but not CD31, CD45 or HLA-DR, showing a conventional MSC phenotype. To investigate the in vitro vessel-forming capabilities, we conducted tube formation assays on Matrigel. The results showed that both EPC and MSC formed tubular structures and EPC showed more branching points (5.8 fold) and larger tube lengths (4.7 fold) compared to MSC ( Figure 1D ).
Increased expression of angiogenic and cardiac protective factors
We determined mRNA expression of angiogenic and cardiac protective factors in late EPC and MSC. qRT-PCR analyses demonstrated that expression levels of Ang-1, FGF-2, SDF1α, and VEGF-A were significantly higher in the MSC compared to the EPC (Figure 2) . However, the anti-apoptotic and cardiomyogenic factor, IGF-1, and an arteriogenic factor, PDGF-B, were significantly higher in the EPC compared to MSC. In addition, levels of PlGF, KDR, CD31, VE-CADHERIN and ANG-2 were higher in EPC compared to MSC. Collectively, these findings suggest that both EPC and MSC are enriched with factors that can benefit vascularization and cardiac protection and that the two types of cells present different types of paracrine factors.
Improvement of cardiac function after EPC or MSC transplantation
We determined the therapeutic effects of direct myocardial transplantation of EPC and MSC in a rat MI model. Echocardiography demonstrated that 4 weeks after cell transplantation, the IVSs, IVSd, LVPWs, LVPWd, EF and FS were significantly greater in the EPC and MSC-transplanted groups compared to the PBS-injected group (Figure 3) . The global cardiac function indices EF and FS were similar between the EPC-and MSC-transplanted groups. The LVESD and LVEDD were lower in the EPC-and MSC-groups than in the PBS group suggesting favorable cardiac remodeling (P < 0.01). These data suggest that despite minor differences, UCB-derived late EPC or MSC transplantation improves global cardiac function and induces favorable remodeling to a similar extent.
Favorable effects of EPC or MSC transplantation on cardiac fibrosis and vascularization
Four weeks after cell transplantation, rats were sacrificed and hearts were harvested, fixed and prepared for histologic examination. Masson's trichrome staining demonstrated that circumferential fibrosis area was significantly smaller in the EPC group, but not MSC group, compared to the PBS group ( Figure 4A ). The infarct wall thickness was greater in the EPCand MSC groups than in the PBS group (430.3 ± 76.9, 426.6 ± 77.9 vs. 374.6 ± 42.6) (P < 0.05) ( Figure 4B ). Capillary density counted after ILB4 staining was significantly higher in the EPC-and MSC groups compared to the PBS group (160.2 ± 26.3, 144.1 ± 24.1 vs. 76.7 ± 13.3) (P < 0.01) ( Figure 4C ).
Cell transplantation increases paracrine factors in ischemic hearts
To determine the levels of paracrine factor expression in the ischemic hearts after cell transplantation, rats were sacrificed and heart tissues were collected from peri-infarct zones at day 7. qRT-PCR analyses demonstrated that the mRNA levels of Ang-2, FGF-2, IGF-1 and SDF-1α were significantly increased in both EPC-and MSC-transplanted groups compared to the PBS-injected group ( Figure 5 ). These data suggest that EPC and MSC transplantation upregulates multiple paracrine factors associated with angiogenesis and cell survival. Intriguingly, the types of increased genes were similar between EPC and MSCtransplanted hearts.
EPC and MSC transplantation decreased apoptosis of myocardial cells
Since biological factors associated with anti-apoptosis and cell survival such as IGF-1, FGF-2, and Ang-2 were increased after cell transplantation, we determined the effects of cell transplantation on myocardial apoptosis and proliferation. We performed TUNEL assay with tissue sections collected from the peri-infarct zones at day 7 (Supplemental Figure 1) . The number of TUNEL positive nuclei was significantly lower in the EPC and MSC groups than in the control group (EPC, MSC vs. PBS, 18.3 ± 2.0, 20.3 ± 2.6 vs. 33.3 ± 4.0, P < 0.01). In addition, we also found that the number of Ki-67 positive cells was significantly higher in the EPC and MSC groups than in the control group (EPC, MSC vs. PBS, 31 ± 3.4, 34 ± 4.7 vs. 10 ± 2.6, P < 0.01).
Low transdifferentiation potential of EPC and MSC into ECs
We next explored the transdifferentiation of EPC and MSC into ECs in vivo. Two weeks after myocardial transplantation of EPC or MSC which were pre-labeled with a red fluorescent dye, CM-Dil, hearts were systemically perfused with ILB4 and the heart tissues were collected. Confocal microscopic examination of peri-infarct and infarct tissues demonstrated that a large number of transplanted DiI-labeled cells were localized in the pericytic or perivascular areas in both EPC and MSC-transplanted cardiac tissues (Figure 6  and 7) . Three-dimensional reconstruction followed by analyses of orthogonal images showed that a small fraction of implanted EPC was colocalized with ILB4-stained ECs (Figure 6 ). In MSC-transplanted heart tissues, most of the MSC were localized at the perivascular areas and only very rarely were incorporated into vascular-like structures expressing ILB4 (Figure 7) . Collectively, these findings suggest that UCB-derived EPC or -MSC have low to minimal transdifferentiation effects and functions mainly through paracrine actions and vascular stabilization at the perivascular area.
Discussion
The present study demonstrated, based on morphologic differences, that late outgrowth EPC and MSC can be derived from UCB via conventional EPC culture conditions. Transplantation of each of these cell types into ischemic myocardium induced effective cardiac repair with EPC being slightly superior in therapeutic potency. This is also the first study to report the therapeutic effects of both UCB-derived late EPC and MSC and to compare their effects side-by-side. Several therapeutic mechanisms were newly demonstrated. First, UCB-derived late EPC or -MSC upregulated various angiogenic, antiapoptotic and cardioprotective factors in the injured hearts during the critical period of infarct repair. The late outgrowth EPC, conventionally known for their robust vasculogenic effects in fact were found to depend more on paracrine actions than direct vasculogenic effects in infarct repair. Second, a majority of EPC and MSC were closely localized to the vessels in the perivascular areas. Although EPC and MSC showed transdifferentiation or direct vasculogenic potential into ECs, it was low in EPC and negligible in MSC. These findings suggest that the neovascularization via UCB-EPC or -MSC occurred through their angiogenic activities and vessel-stabilizing effects.
Cell therapy with BM or peripheral blood-derived cells has shown favorable yet modest effects on cardiac repair in patients with ischemic heart disease [33] . Many studies have reported that paracrine or humoral effects are a major therapeutic mechanism of these EPC or MSC in cardiovascular regeneration [5, 13, 32, 34] . In the present study, we found that similar mechanisms underlie the therapeutic effects of cord blood-derived late outgrowth EPC and MSC.
Several prior studies have demonstrated that late outgrowth EPC derived from peripheral blood induce neovascularization mainly through direct transdifferentiation into ECs (or vasculogenesis) [10, 35, 36] . However, our confocal examination demonstrated that such transdifferentiation can occur, but to a lesser degree than can explain increased vasculature and therapeutic effects. This is arguably the first report that late outgrowth EPC have weak vasculogenic or endothelial transdifferentiation effects in the ischemic tissues. Rather, we found that UCB-derived late outgrowth EPC are enriched with factors associated with vessel formation and tissue protection such as Ang-2, IGF-1, and PDGF-B. Of interest, representative angiogenic factors such as VEGF-A, FGF-2 and Ang-1 and a chemoattractant factor, SDF-1 were more highly expressed in MSC compared to EPC. Ang-2 is conventionally known for its vascular destabilizing effects while Ang-1 is associated with vessel stabilization [37] . However, recent publications suggested that Ang-2 plays a crucial role in ischemia-and hypoxia-induced vascular remodeling and arteriogenesis [38, 39] . Increased Ang-2/Ang-1 ratio promotes blood vessel sprouting and potentiates EC's responsiveness to VEGF [40, 41] . Another study reported that VEGF and excess Ang-2 lead to the formation of a greater number of small vessels [42] . PDGF signaling plays an important role in cardiovascular homeostasis. Deletion of PDGF-B and its receptor results in cardiac abnormalities and endothelial-specific ablation of PDGF-B leads to myocardial abnormalities due to vasculogenic defects such as pericyte loss [43, 44] . PDGF-B overexpression was shown to protect myocardium after infarction [45] . IGF-1, a well-known anti-apoptotic factor, attenuates myocardial fibrosis and interferes with necrosis during ischemia injury [46] . IGF-1 increases membrane stability of cells by Bcl-2 expression, releasing nitric oxide which prevents cardiomyocyte apoptosis [47, 48] .
While there were certain differences in the types of paracrine factors between EPC and MSC in vitro, no significant differences were noted in the types of increased paracrine factors in the heart tissues after cell transplantation. Among those increased factors, SDF-1 is known for its effects on protection of myocardium by mobilizing BM cells, and IGF-1 and HGF play an important role in preventing adverse remodeling, as these factors protect cardiomyocytes from apoptosis and induce proliferation of resident cardiac stem cells for neovascularization and cardiomyogenesis [49, 50] . Recently, we demonstrated that initial up-regulation of paracrine factors is attributed to both transplanted cells and host cells and sustenance of such up-regulation after several days is almost solely due to host myocardial cells in infarcted myocardium transplanted with BM-derived early EPC [32] . The current results support this finding by showing no difference in the upregulated factors at one week regardless of the types of transplanted cells, due to the dominant contribution of host myocardium-derived humoral factors. Our prior paper in which BM-derived early EPC were similarly transplanted to mouse MI also demonstrated that SDF-1, IGF-1 and HGF are the most robustly increased factors in the first two weeks, the most critical period for infarct repair and remodeling. Together these results suggest that similar paracrine factors are involved in the injured heart following adult stem or progenitor cell transplantation for cardiac repair.
In earlier studies, transdifferentiation of BM-derived early EPC or MSC into endothelial cells or cardiomyocytes was reported as the major therapeutic mechanism; however, later studies found that such potential is minimal and the extent and durability of transdifferentiation were not sufficient to explain the therapeutic effects in cardiovascular animal models [5, 13, 28] . On the other hand, studies have demonstrated that late outgrowth EPC derived from human circulation are closer to genuine EC than early EPC, and have higher endothelial generation potential in vivo [51] . These robust vasculogenic capabilities of late EPCs were highlighted as advantages for cardiovascular cell therapy [10, 35, 36, 51] . Our current study, however, demonstrated that the fate of injected UCB-derived late EPC in ischemic hearts is similar to other BM-derived cells including early EPC [14, [52] [53] [54] [55] [56] . Extensive confocal microscopic examination revealed less than 1% transdifferentiation into endothelial cells in UCB-EPC and -MSC transplanted cardiac tissues. Thus, these results suggest that late outgrowth EPC do not have high endothelial transdifferentiation potential, at least in the setting of MI, and function through paracrine effects for cardiac repair similar to other adult stem or progenitor cells. Cardiomyocyte transdifferentiation was not found. As reported with BM-derived EPC or MSC, most of the engrafted UCB-EPC and -MSC were located at pericytic or perivascular areas, suggesting the vessel stabilizing effects of these cells [29, 32, 57, 58] ,.
Together, our data indicate that intramyocardial implantation of UCB-derived late EPC or MSC can efficiently induce myocardial repair to a similar extent, and humoral factors and perivascular localization of transplanted cells mainly mediate such therapeutic effects. These UCB-derived EPC or MSC can be attractive and promising cell sources for cardiovascular cell therapy.
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